Research analysts at BMO Capital Markets began coverage on shares of MediPharm Labs (OTCMKTS:MEDIF) in a research note issued to investors on Friday, The Fly reports. The brokerage set a “market perform” rating on the stock.
Separately, Canaccord Genuity dropped their price target on MediPharm Labs from $1.75 to $1.00 and set a “buy” rating on the stock in a research report on Thursday, April 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $1.38.
Shares of MediPharm Labs stock opened at $0.37 on Friday. The business’s 50 day simple moving average is $0.41 and its 200-day simple moving average is $0.51. MediPharm Labs has a twelve month low of $0.35 and a twelve month high of $1.53.
MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates, and advance derivative products in Canada and Australia. It formulates, processes, packages, and distributes cannabis extracts and cannabinoid-based products. The company was founded in 2015 and is headquartered in Barrie, Canada.
Read More: What is a conference call?
Receive News & Ratings for MediPharm Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediPharm Labs and related companies with MarketBeat.com's FREE daily email newsletter.